NEW YORK — Once-daily Rhopressa treatment for patients with ocular hypertension or open-angle glaucoma consistently demonstrated IOP-lowering effects over 6 months and was noninferior to timolol, according to a speaker here.
“Netarsudil was noninferior at baseline pressures below 30 mm Hg, but also at lower baseline pressures, which is very important, below 27 mm Hg and below 25 mm Hg. When patients have a lower baseline pressure, medications struggle at being effective. This was noninferior to timolol even in patients with a baseline pressure below 25 mm Hg,” Albert Khouri,
Uncategorized